Clinical trial
A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 26-week Study Comparing the Efficacy and Safety of Once-weekly Insulin Icodec and Once-daily Insulin Glargine U100, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- August 11, 2025
- Completion date
- March 1, 2027
- Enrollment
- 877 (estimated)
- Sites
- 182
Conditions
As the registry lists them; a condition with its own page is linked.